Theprubicin
Advanced Adult Hepatocellular Carcinoma
Shenzhen SiBiono GeneTech Co.,LtdSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Advanced Adult Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Roswell Park Cancer Institute | Phase 3 | BBB |
Ethiodized Oil Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 | B |
Epirubicin Roswell Park Cancer Institute | Phase 1/2 | B |
Everolimus UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Crcl Mirror Biologics, Inc. | Phase 2 | B |
View all 18 →
Same molecule, other indications
Theprubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →